This article is part of our special focus on "traditional" pharma: The Small Molecule Manufacturer (read more here). You can find more articles from The Small Manufacturer here.
Researchers at the University of Cambridge have developed a metal-organic framework (MOF) that helps deliver cancer drug candidates directly to mitochondria (1).
According to David Fairén-Jiménez, a researcher at the university, the MOFs developed by his team enter the cells via receptor-mediated endocytosis, “smuggling” drugs into mitochondria. “We loaded our MOFs with dichloroacetate, an anticancer drug candidate currently undergoing clinical trials, and found that the drug-loaded MOFs can reduce the drug dose needed to kill cancer cells, something that could lessen the side-effects of chemotherapy,” he said (2).
Fairén-Jiménez admits the research is just “one piece in a jigsaw” of effort around the possibilities of MOFs for targeted drug delivery. His group is currently expanding its work to investigate the potential of different MOFs, anticancer drugs, and coatings.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
References
- S Haddad et a.l, “Design of a Functionalized Metal–Organic Framework System for Enhanced Targeted Delivery to Mitochondria”, J Am Chem Soc, 142, 6661, (2020).
- Chemistry World, “MOF delivers cancer drug candidate straight to mitochondria”, 2020. Available at: https://bit.ly/3boP0FR
